PMEL and uveal melanoma: Recently, a T cell engager medication comprisinga bispecific fusionanti-CD3 protein targeting gp100 membrane antigen (Tebentafusp) hasshown potent antitumor response with significant improvement of overallsurvival at 1 year in patients with metastatic refractory melanoma60,77 and HLA-A*02:01-positive uveal melanoma patients78 for which it gained FDA approval in 2022.